Connection

Yazdan Yazdanpanah to Administration, Oral

Back to Details
This is a "connection" page, showing publications Yazdan Yazdanpanah has written about Administration, Oral.
Yazdan Yazdanpanah
Connection Strength
0.051
Administration, Oral
  1. Population pharmacokinetics of Rilpivirine in HIV-1-infected patients treated with the single-tablet regimen rilpivirine/tenofovir/emtricitabine. Eur J Clin Pharmacol. 2018 Apr; 74(4):473-481.
    View in: PubMed
    Score: 0.026
  2. Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial. Lancet HIV. 2017 11; 4(11):e486-e494.
    View in: PubMed
    Score: 0.025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.